Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.

Subheading

A case study investigating the short-term efficacy and tolerability of a daily serum composed from a unique sunflower sprout extract

October 21, 2022

Read More

A multi-functional anti-aging moisturizer maintains a diverse and balanced facial skin microbiome.

October 21, 2022

Read More

Treatment of Periorbital Facial Wrinkles in Female Subjects: A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Split-Face Study Evaluating Procedure Pairing of a Peptide Anti-Aging Serum with Onabotulinumtoxina.

October 21, 2022

Read More

A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines.

October 21, 2022

Read More

A Randomized, Double-Blind, Split-Body, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Tolerability of a Topical Body Firming Moisturizer for Upper Arm Rejuvenation.

October 21, 2022

Read More

Clinical Study to Evaluate the Efficacy and Tolerability of Cosmeceuticals Targeting the Dermal-Epidermal Junction.

October 21, 2022

Read More

Effective lightening of facial melasma during the summer with a dual regimen: A prospective, open-label, evaluator-blinded study.

October 21, 2022

Read More

An open-label, single-site study to evaluate the tolerability, safety, and efficacy of using a novel facial moisturizer for preparation and accelerated healing pre and post a single full-face radiofrequency microneedling treatment.

October 21, 2022

Read More

An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin.

October 21, 2022

Read More

An Open Label Clinical Trial to Evaluate the Efficacy and Tolerance of a Retinol and Vitamin C Facial Regimen in Women With Mild-to-Moderate Hyperpigmentation and Photodamaged Facial Skin.

October 21, 2022

Read More

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.

September 09, 2022

Read More